1. Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. (13th June 2016) Authors: Lentz, S. R.; Cerqueira, M.; Janic, D.; Kempton, C.; Matytsina, I.; Misgav, M.; Oldenburg, J.; Ozelo, M.; Recht, M.; Rosholm, A.; Savic, A.; Suzuki, T.; Tiede, A.; Santagostino, E. Journal: Haemophilia Issue: Volume 22:Number 5(2016:Sep.) Page Start: e445 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial. (8th June 2015) Authors: Ozelo, M.; Misgav, M.; Abdul Karim, F.; Lentz, S. R.; Martin‐Salces, M.; Matytsina, I.; Saugstrup, T.; Santagostino, E. Journal: Haemophilia Issue: Volume 21:Number 5(2015:Sep.) Page Start: e436 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials. (2nd October 2014) Authors: Santagostino, E.; Lentz, S. R.; Misgav, M.; Brand, B.; Chowdary, P.; Savic, A.; Kilinc, Y.; Amit, Y.; Amendola, A.; Solimeno, L. P.; Saugstrup, T.; Matytsina, I. Journal: Haemophilia Issue: Volume 21:Number 1(2015:Jan.) Page Start: 34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗